© 2020 Recharge Biomedical
Exosomes and TA-65 are not FDA-approved to prevent or treat any illness
Perhaps the better disease paradigm is that the ongoing clearance of bad cells and waste is a result of the evolutionary elegant design of the blood-brain barrier, which keeps the younger, more capable bone marrow-derived immune cells from entering this space.
Reading Time: < 1 minute
Promising Alzheimer’s therapy suggests alternative disease origin
Tip of the hat to my friend, Loren, who posted this article about an Australian team of researchers that improved mice Alzheimer’s by 75%
They used ultrasound beams to open up the blood-brain barrier, resulting in improved microglial clearance of the junk proteins associated with the disease. Microglial are the Praetorian guard macrophages of the central nervous system.
As we discussed in my interview with Dr. Michael Fossel, a medical doctor planning trials for telomerase gene therapy to treat Alzheimer’s, the microglia fail to do their job properly in Alzheimer’s and we discussed whether the problem isn’t that the microglia are relatively old and dysfunctional because you rarely get new recruits from the outside immune system that can enter unless there is brain inflammation. Some believe the majority of the microglia were there since you were an embryo.
Perhaps the better disease paradigm is that the inefficient clearance of bad cells and waste is a result of the evolutionary elegant design of the blood-brain barrier, which keeps the younger, more capable bone marrow-derived immune cells from entering this space.
To learn about telomeres and Alzheimer’s, listen to this interview that I did with Dr. Fossel:
